cancer

A New Pathway To Kill Resistant Breast Cancer

As all the recent news about protein folding should make clear, there are a lot of ways for any given protein sequence to come together into a three-dimensional structure. For that phrase “a lot”, substitute “a larger number than the human mind can possibly comprehend”, and you’ll be about right. Biologically, many proteins already display …

A New Pathway To Kill Resistant Breast Cancer Read More »

Dr. Greger’s Daily Dozen Healthiest of Healthy Foods 

In my book How Not to Die, I center my recommendations around a Daily Dozen checklist of everything I try to fit into my daily routine.  In my book How Not to Die, I suggest we try to center our diets around whole plant foods. Some plants are healthier than others, though. Apparently, you can live for extended periods eating practically nothing but white potatoes, for example, …

Dr. Greger’s Daily Dozen Healthiest of Healthy Foods  Read More »

Amgen adds antibody assets and R&D tech with $900M Teneobio acquisition

Amgen is paying $900 million up front to acquire Teneobio, a biotech with technology for discovering and developing antibody drugs. Though Amgen already has its own antibody platform, the company says Teneobio’s technology and drug assets will complement its own.

Is medical cannabis really a magic bullet?

Research increasingly suggests that extracts from the plant are effective in treating pain, anxiety, epilepsy and more, but experts still preach caution around recreational use In 2017, Mikael Sodergren, a liver and pancreatic cancer surgeon at Imperial College healthcare NHS trust, was finding himself becoming increasingly interested in the potential role of medical cannabis in …

Is medical cannabis really a magic bullet? Read More »

Frontier Medicines raises $88M for R&D, including potential rival to Amgen cancer drug

Cancer drug developer Frontier Medicines already has a research partnership with AbbVie. Now the preclinical-stage biotech has raised $88.5 million for its own pipeline, including a drug that could offer advantages over a recently approved Amgen cancer therapy.

Wugen unveils $172M to take natural killer cell therapies to solid tumors

Wugen, a biotech developing “off-the-shelf” natural killer and CAR T cell therapies, has raised $172 million in Series B financing. The company’s lead program has already reached human testing and the new capital will be used to continue that research and advance other pipeline programs to the clinic.

A Fifty-Year-Old Cancer Drug Doesn’t Do What You Think

5-fluorouracil (5-FU) has been around a long time now (over fifty years), and it’s a standard oncology drug (particularly in colorectal treatment regimes). But try going around and asking people how it works. If you’re talking to a clinician and want to seem up on the lingo, just say “What’s 5-FU’s MOA?” (mechanism of action). …

A Fifty-Year-Old Cancer Drug Doesn’t Do What You Think Read More »

Elekta to work with academics on AI-directed radiotherapy

Radiotherapy specialist Elekta has joined forces with two academic groups in the Netherlands to explore the use of artificial intelligence (AI) to deliver more effective personalised therapy to patients.  The Swedish company will collaborate with scientists at the Netherlands Cancer Institute and University of Amsterdam (UvA) on a project that aims to use AI to …

Elekta to work with academics on AI-directed radiotherapy Read More »

What HCPs think about health equity in cancer care

After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in healthcare. CREATION.co’s Mary Kangley explores what HCPs think about health equity in cancer care. The topic rose to significance in the American Society of Clinical Oncology (ASCO) whereby they updated …

What HCPs think about health equity in cancer care Read More »

Oil Pulling for Cancer? 

What evidence exists to suggest oil pulling can effectively treat serious diseases, such as paralysis, meningitis, cancer, and AIDS?  I’ve produced videos on how coconut oil is safe to put on your hair or put on your skin, but you certainly don’t want to eat it. In fact, you may not even want to be in the same kitchen when coconut oil is being heated. I don’t know where people got the idea …

Oil Pulling for Cancer?  Read More »

Biotech startup using AI to take guesswork out of cancer drug selection raises $70M

Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.

Health Innovators: Eliot Forster, F-Star

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the lives of patients with cancer.     About the author Dr Paul Tunnah is chief content officer and UK managing director for Healthware Group, a next-generation integrated consulting group that …

Health Innovators: Eliot Forster, F-Star Read More »

What mRNA is Good For, And What It Maybe Isn’t

The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. Moderna and BioNTech, of course, have been thinking this way for quite some time. But Sanofi now says that they’ll be investing large amounts into the technology, and this previously hadn’t been …

What mRNA is Good For, And What It Maybe Isn’t Read More »

Novobiocin Returns? But Not as an Antibiotic.

Here’s some interesting work from Dana-Farber (earlier BioRxiv version here) that may turn into a rare example of repurposing an old drug, if it works out. The team was studying an enzyme called DNA polymerase theta (also known by its corresponding gene name, POLQ), which is one of the lesser-known members of that functional family. …

Novobiocin Returns? But Not as an Antibiotic. Read More »

Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials

Lyell Immunopharma and Verve Therapeutics are still preclinical, but they’re bring novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two of the biggest biotech IPOs of 2021 so far.

Goal Attainment Scaling

What outcomes should be used to measure if a medicine is a “good” medicine? Improved survival? Improved ability to function? Few side effects? Ability to get back to work? Living to attend your daughter’s wedding? All of the above? Oftentimes, health economists measure value of a treatment for the average person. Preferences for efficacy, safety, …

Goal Attainment Scaling Read More »

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer

Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will share global development costs of EOS-448 and co-commercialize & share profits in the US GSK to receive an exclusive license for commercialization (Ex-US) & access …

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer Read More »

ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more

The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.

INVEST Precision Medicine conference kicks off today. Register now to be part of the conversation.

Register for the INVEST Precision Medicine conference, which kicks off today. Over the next three days industry experts will talk about precision medicine developments across pediatrics, bioinformatics, startups and more.

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Dr Jay Mei, founder and …

Country focus: China & APAC’s growing medical needs bring opportunities and challenges Read More »

Merus eyes tumor-agnostic path for cancer drug addressing rare genetic target

Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.

Auris Medical pivots from hearing loss drugs, joins red hot RNA therapies field

Auris Medical has acquired Trasir Therapeutics, a startup developing technology that expands the delivery of RNA medicines to tissues beyond the liver. Going forward, Auris will sell or spin off its programs in hearing disorders and allergies and focus exclusively on RNA therapies.

Changing focus to cachexia may be key to improved cancer outcomes

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses the historial challenges to developing a therapeutic for this condition and what may finally be on the horizon.  Until recently, cancer research and resulting therapeutic approaches have focused on one …

Changing focus to cachexia may be key to improved cancer outcomes Read More »

MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.

AI Disease Modeling Supports Precision Medicine for Cancer

Precision medicine has offered a lot of hope for the treatment of cancer, as it makes it possible to tackle the multi-faceted disease with a more personalized, patient-specific approach. Meanwhile, researchers are also becoming increasingly interested in applications for artificial intelligence in the development of drugs and therapies. Could AI and precision medicine work together …

AI Disease Modeling Supports Precision Medicine for Cancer Read More »

Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies

Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, “deciphering biology” to find new cancer drugs.

Tomato Sauce Put to the Test for Prostate Cancer

What happened when cancer patients were given three quarters of a cup of canned tomato sauce every day for three weeks? “Occasionally…positive things happen in the field of cancer prevention science to popular, good-tasting foods.” Cruciferous vegetables like broccoli are wonderful, but they may be “a hard food for the public to swallow.” By contrast, …

Tomato Sauce Put to the Test for Prostate Cancer Read More »

Lycopene Supplements Put to the Test

High doses of lycopene—the red pigment in tomatoes—were put to the test to see if it could prevent precancerous prostate lesions from turning into full-blown cancer. Back in 1980s, the Adventist Health Study found “strong protective relationships” against prostate cancer with increasing consumption of legumes, citrus, dried fruit, nuts, and tomatoes. In the 1990s, a …

Lycopene Supplements Put to the Test Read More »

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed their potential as next-generation cancer immunotherapies. Bristol-Myers Squibb made a splash ahead of the virtual conference early next month, with results showing a single infusion of its LAG-3 blocker relatlimab …

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies Read More »

Numab raises $110m to develop cancer bispecific antibodies

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. Proceeds will support acceleration and expansion of the clinical development of Numab’s lead drug NM21-1480 into several cancer indications. It …

Numab raises $110m to develop cancer bispecific antibodies Read More »

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda. The companies filed for approval for the PD-1 inhibitor in untreated nonsquamous non-small lung cancer in combination with pemetrexed and platinum chemotherapy. It’s the first …

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option Read More »

BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the TIGIT receptor that is emerging as an immunotherapy target. Roche is one of the leaders in research in to TIGIT – short for …

BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug Read More »

Amla (dried Indian gooseberry) vs. Lipitor for Lowering Cholesterol

Extracts of amla (Indian gooseberry) were pitted head-to-head against cholesterol-lowering statin drugs and the blood thinners aspirin and Plavix. Indian gooseberries, otherwise known as amla, have been touted as everything from a cancer fighter to a hair tonic to a refrigerant. (A refrigerant? Like Freon?) Amla’s even been labeled a snake venom detoxifier—but based on …

Amla (dried Indian gooseberry) vs. Lipitor for Lowering Cholesterol Read More »

‘Kicking You When You’re Down’: Many Cancer Patients Pay Dearly for Parking

For cancer patients, the road from diagnosis to survivorship feels like a never-ending parade of medical appointments: surgeries, bloodwork, chemotherapy, radiation treatments, scans. The routine is time-consuming and costly. So, when hospitals charge patients double-digit parking fees, patients often leave the garage demoralized. This story also ran on NBC News. It can be republished for …

‘Kicking You When You’re Down’: Many Cancer Patients Pay Dearly for Parking Read More »

The Most Antioxidant-Packed Whole Food

Are the apparently amazing benefits of amla—dried Indian gooseberries—too good to be true? In reference to amla, also known as the Indian gooseberry, it’s been said that “medicinal plants are nature’s gift to human beings to promote a disease free healthy life.” The fruit has also been described as “the Ayurvedic wonder.” You hear a …

The Most Antioxidant-Packed Whole Food Read More »

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impressive. To recap, AZ shelled out $1bn for rights to datopotamab last year, an antibody-drug conjugate (ADC) consisting of an antibody that targets tumours and a lethal …

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan Read More »

Redesign Health Spinout Jasper Health Launches AI-Driven Cancer Care Platform

What You Should Know: – Jasper Health launched today as the first end-to-end care experience that navigates, connects, and provides actionable insights throughout the cancer journey for individuals with cancer, their caregivers, and providers. – Jasper combines an easy-to-navigate user interface with leading oncology support to help guide Jasper Members and caregivers through the myriad …

Redesign Health Spinout Jasper Health Launches AI-Driven Cancer Care Platform Read More »

Mayo Clinic strikes remote patient monitoring partnership with NXgenPort

Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. This latest agreement follows a major deal with Vertex last month, where CRISPR announced it is to receive $900m in a reworked collaboration, to develop a gene editing therapy for sickle cell disease …

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta Read More »

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer?

Avocado consumption can improve artery function, but what effect might guacamole have on cancer risk? In my last video about avocados, The Effects of Avocados and Red Wine on Meal-Induced Inflammation, I described their anti-inflammatory effects and cholesterol- and triglyceride-lowering effects, but what about the Are Avocados Good for You? video I did years ago …

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer? Read More »

Cancer Centers: Here’s How We Can Restart Clinical Trials Today

Marie E. Lamont, President and COO of Inteliquet Biopharmaceutical companies developing cancer treatments need to restart the clinical trials shut down or delayed during the early stages of the coronavirus pandemic. Some are holding back, however, due to a lack of confidence that sufficient eligible patients can be recruited and enrolled in the trials. Recruiting …

Cancer Centers: Here’s How We Can Restart Clinical Trials Today Read More »

Roche’s Tecentriq gets fourth European lung cancer indication

Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) has now been used in Europe for adults with metastatic NSCLC whose tumours have high PD-L1 expression. The tumours must also have no epidermal growth factor …

Roche’s Tecentriq gets fourth European lung cancer indication Read More »

Natural Dietary Treatments for Fibroids

The same diet that helps regulate hormones in women may also reduce exposure to endocrine-disrupting pollutants. Fibroids are the most common benign tumors in women. They can grow to a foot in diameter and affect the majority of women before they hit menopause. Although fibroids tend to be asymptomatic, when symptoms do occur, they tend …

Natural Dietary Treatments for Fibroids Read More »

Two new biotechs unveil $112M combined for antibody drug conjugates for cancer

The list of FDA-approved antibody drug conjugates (ADC) is growing, and two more biotech startups have emerged from stealth with new cash and new approaches to this type of cancer drug. Adcendo and Adcentrx raised a combined $112 from their Series A financings.

Two Steps to Activation

Engineering immune system cells to do what we’d like them to do is one of the big areas of medical research these days, and this new paper could be a real advance in the area. A team out of UCSF with several collaborators reports on a new way around one of the big problems in …

Two Steps to Activation Read More »

Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say

Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs. Tecentriq was the first drug to be discussed in the review by the FDA’s Oncologic Drugs Advisory Committee (ODAC) of cancer drugs that …

Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say Read More »

FDA approves under-pressure GSK’s Jemperli for endometrial cancer

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.  With Jemperli, a PD-1 class drug, GSK is a latecomer to the immunotherapy party with a host of other competitors already on the market in various cancers. Merck & Co’s Keytruda …

FDA approves under-pressure GSK’s Jemperli for endometrial cancer Read More »

Centessa plans $100m IPO to fund R&D and potential acquisitions

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in private backing and an R&D powerhouse driven by the merger of 10 biotechs. In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs …

Centessa plans $100m IPO to fund R&D and potential acquisitions Read More »

Regulatory progress for two biotechs stalls as FDA requests more information

The FDA placed a clinical hold on a KalVista Pharmaceuticals drug being readied for mid-stage studies in a rare, inherited disorder. Meanwhile, the FDA has some questions about the historical data Y-mAbs used as the control in a clinical trial for its antibody cancer drug.

NorthShore, Sema4 set up genomics program to advance personalized treatment

The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.

Should You Get an Annual Physical Exam?

What are the risks and benefits of getting a comprehensive annual physical exam and routine blood testing? The model of getting an annual physical exam dates back nearly a century in American medicine, but recently, many health authorities “have all agreed that routine annual checkups for healthy adults should be abandoned”—yet, the majority of the …

Should You Get an Annual Physical Exam? Read More »

J&J decides against Erleada+Zytiga combination prostate cancer filing

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it didn’t improve survival compared with Zytiga alone. Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the …

J&J decides against Erleada+Zytiga combination prostate cancer filing Read More »

Non-Small Cell Lung Cancer Drug Development Summit

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies, either in combination or …

Non-Small Cell Lung Cancer Drug Development Summit Read More »

Activist investor Elliott builds stake in GSK after fresh trial upset

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn around the company’s fortunes. The news follows another trial disappointment this week, where GSK’s feladilimab, combined with Merck & Co’s Keytruda (pembrolizumab), came up short in a …

Activist investor Elliott builds stake in GSK after fresh trial upset Read More »

C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform

– Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. – Funds will be used to accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a cancer diagnostics service, that uses AI pattern recognition and whole-genome …

C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform Read More »

Should You Get an Annual Health Check-Up?

What are the risks and benefits of getting an annual check-up from your doctor? Physicians and patients have come to expect the annual check-up as a routine part of care. “However, considerable research has not demonstrated a substantial benefit,” so a “revolt is brewing against the tradition of periodic” check-ups. “Even the Society for General …

Should You Get an Annual Health Check-Up? Read More »

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.  The collaboration was launched in 2019 and in its next phase will explore new molecules from Boehringer’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios, with a …

Boehringer and MD Anderson extend KRAS cancer collaboration Read More »

Gilead’s Trodelvy approved in metastatic urothelial cancer

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer.  Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy. The US pharma hopes that the drug will be used in those patients who have not …

Gilead’s Trodelvy approved in metastatic urothelial cancer Read More »

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.  The drug has gone on to become a huge success, generating sales of nearly $1.8 billion in 2020 alone as part of a partnership with Merck & Co after expanded use in …

AZ aims at Pfizer, GSK with potential new PARP cancer drug Read More »

Biotech startup Repertoire adds $189M to expand array of immune medicines

With two cancer programs already making progress, Repertoire Immune Medicines will use the Series B financing to expand its immune synapse research to autoimmune disorders and infectious disease. CEO John Cox said his startup’s approach could advance immune medicines beyond the scope of currently available therapies.

Do Cell Phones Cause Brain Tumors?

What does the world’s leading authority on carcinogens have to say about mobile phones? Do cell phones cause cancer? That’s a question billions of people would like to have answered and one I address in my video Cell Phone Brain Tumor Risk?. That’s why we have the World Health Organization’s International Agency for Research on …

Do Cell Phones Cause Brain Tumors? Read More »

Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption

What You Should Know: – Philips and Ibex Medical Analytics announced a strategic partnership to globally commercialize clinically proven, AI-powered digital pathology solutions. The collaboration further cements Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis. – The trend towards centralized pathology labs, the global shortage of trained pathologists, and increasing demands on histopathology …

Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption Read More »

Can Cell Phone Radiation Damage Your DNA?

Do mobile phones cause brain tumors? Whenever a trillion-dollar industry is involved—whether it’s Big Food, Big Tobacco, Big Pharma, or Big Telecom—there’s so much money that the science can get manipulated. When it comes to the potential human health effects of cell phone use, certainly, you might end up with a crick in your neck …

Can Cell Phone Radiation Damage Your DNA? Read More »

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced suite of technology solutions designed to help oncologists improve outcomes, …

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching Read More »

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases

That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, John R. Penrod, and John A. Romley. The subtitle is A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer. The full abstract is below: Objectives: To compare …

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases Read More »

Is Cocamidopropyl Betaine in Toothpaste Better Than Sodium Lauryl Sulfate?

For those with recurrent canker sores, is it better to use a toothpaste with SLS, CAPB, or no foaming agents at all? Sodium lauryl sulfate (SLS) had already been used as a foaming agent in toothpastes for more than a half-century by the time a study was published showing tissue damage in most of those …

Is Cocamidopropyl Betaine in Toothpaste Better Than Sodium Lauryl Sulfate? Read More »

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

Shots: The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality, safety & efficacy …

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer Read More »

Is Sodium Lauryl Sulfate (SLS) in Toothpaste Safe?

Just because the sodium lauryl sulfate in toothpaste doesn’t cause cancer doesn’t mean it can’t cause problems. Sodium lauryl sulfate (SLS) is a common detergent used in toothpaste. It was featured in a famous Internet hoax nearly 20 years ago. Colgate toothpaste contains SLS, which was supposedly proven to cause cancer, but at least buying …

Is Sodium Lauryl Sulfate (SLS) in Toothpaste Safe? Read More »

COVID Exposed The Dire Need for Real-Time Healthcare Data Sharing

Birju Shah, Head of Product for Uber Health & Communities Nick Jordan, Founder and CEO, Narrative In a world where technology and Big Data can provide us with instantaneous access to our banking transactions, and our financial information and credit reports can be retrieved with a few keystrokes when applying for a mortgage — trying to …

COVID Exposed The Dire Need for Real-Time Healthcare Data Sharing Read More »

Helpful Foods to Support People with Autism

The sulforaphane found in five cents’ worth of broccoli sprouts has been shown to benefit autism in a way no drug ever has in a randomized, double-blind, placebo-controlled study. You may remember my series of videos, which includes Prevent Cancer from Going on TOR, about target of rapamycin (TOR), the engine-of-aging enzyme. Kids with autism …

Helpful Foods to Support People with Autism Read More »

Getting a Prescription to Die Remains Tricky Even as Aid-in-Dying Bills Gain Momentum

Linda Heim knew her dad didn’t plan to wait for the cancer to kill him. For decades, he’d lived in Montana, which they’d thought was one of the few places where terminally ill people could get a prescription to end their life. This story also ran on Time. It can be republished for free. After …

Getting a Prescription to Die Remains Tricky Even as Aid-in-Dying Bills Gain Momentum Read More »

Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model

What You Should Know: – Omega Healthcare, a provider of outsourced revenue cycle management and other healthcare support services, today announced the acquisition of himagine Solutions, a St. Louis based provider of medical coding and registry services. The transaction expands the service capabilities and geographical footprint of both companies, enhancing the ability to service clients globally. – Through this acquisition Omega Healthcare will …

Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model Read More »

To Advance Health Equity, Put Real-World Cancer Data to Work

Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health conditions, for example, …

To Advance Health Equity, Put Real-World Cancer Data to Work Read More »

COSMIC database matches drugs to cancer mutations

The world’s largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out of the work of the Cancer Genome Project and has …

COSMIC database matches drugs to cancer mutations Read More »

Cancer services should be rebuilt after COVID disruption, experts say

There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry. The Association of the British Pharmaceutical Industry (ABPI) report said that the UK must be more ambitious with its cancer strategy if it is to compete with …

Cancer services should be rebuilt after COVID disruption, experts say Read More »

NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M

What You Should Know: – NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35 million in cash on hand and $30 million in NeoGenomics …

NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M Read More »

Instil Bio’s upsized IPO raises $320M for clinical tests of TIL cancer cell therapy

Instil Bio, one of several companies developing tumor-infiltrating lymphocytes, will use its IPO cash to advance its clinical testing plans. Meanwhile, Finch Therapeutics and Gain Therapeutics also priced IPOs to fund clinical trials.

How do you get all the data quality benefits of eCOA in less time and at lower cost?

Upcoming oncology trial? Which oncology eCOA Package offers the best ability to capture reliable endpoint evidence to increase speed, reduce cost, and ensure consistency across sites and geographies in less time? Find out. Consider these data points: 334 studies 158,000+ patients 67 countries 44,000+ sites 116 languages 30+ indications 33% Faster Design with an Average …

How do you get all the data quality benefits of eCOA in less time and at lower cost? Read More »

Benefits of Turmeric for Arsenic Exposure

What happened when turmeric curcumin was put to the test to see if it could reverse DNA damage caused by arsenic exposure? Arsenic is a carcinogenic heavy metal, and the major mechanism of arsenic-related damage appears to be oxidative stress. It’s the arsenic-induced accumulation of free radicals that can kill off cells and damage our …

Benefits of Turmeric for Arsenic Exposure Read More »

Achieving Financial Sustainability: A Connected Community of Care’s #1 Goal

Dr. Keith Kosel, Vice President at Parkland Center for Clinical Innovation (PCCI) “Show me the money!” No one old enough to have seen the 1996 movie, Jerry Maguire, will ever forget that memorable phrase. That simple but powerful phrase could apply to every person who punches a clock for a living and just about every …

Achieving Financial Sustainability: A Connected Community of Care’s #1 Goal Read More »

Aveo Oncology’s kidney cancer drug gets FDA nod, 8 years after stinging rejection

In two pivotal studies years apart, Aveo Oncology’s drug tivozanib did not help kidney cancer patients live longer overall compared to the standard of care. The FDA approved still approved it, the latest development in a long saga that includes several regulatory stumbles.

Are Lectins in Food Good or Bad for You?

Might lectins help explain why those who eat more beans and whole grains have less cancer? Lectins are to blame for the great “white kidney bean incident” of 2006 in Japan. One Saturday evening, a TV program introduced a new method to lose weight. The method was simple: toast some dry, raw, white kidney beans …

Are Lectins in Food Good or Bad for You? Read More »

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace. San Francisco-based Maverick’s technology is designed to target solid tumours with a T-cell attack that focuses on cancerous tissues while leaving healthy tissue alone. Standard T-cell …

Takeda buys Maverick as T-Cell engager research hots up Read More »

How to Avoid Lectin Poisoning

How should we properly cook beans? In the 1800s, a compound was discovered in castor beans, which we would come to know as the first of a class of lectin proteins, natural compounds found throughout the food supply, but concentrated in beans, whole grains, and certain fruits and vegetables. Every decade or two, a question …

How to Avoid Lectin Poisoning Read More »

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

Roche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that have failed to live up to their early promise. The Swiss pharma said it is voluntarily withdrawing the US indication for the immunotherapy Tecentriq (atezolizumab) in metastatic urothelial carcinoma (mUC) previously treated with chemotherapy. As with AstraZeneca’s …

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues Read More »

Novartis’ canakinumab falls short in phase 3 lung cancer trial

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. Already approved for auto-inflammatory diseases such as active systemic juvenile idiopathic arthritis under the brand name Ilaris, Novartis is testing canakinumab to see if inhibiting the IL-1beta pathway can …

Novartis’ canakinumab falls short in phase 3 lung cancer trial Read More »

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. …

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy Read More »

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Shots: The company reported the voluntary withdrawal of the Tecentriq (atezolizumab) indication in the US for prior-platinum treated mUC, bladder cancer The withdrawal was made in consultation with the US FDA to review the accelerated approvals with confirmatory trials that have not met 1EPs and have yet to gain regular approvals. The decision does not …

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US Read More »

BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials

What You Should Know: –BioIntelliSense announced it has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate the BioSticker™ platform in clinical trials of hematological cancer patients. – The LLS clinical trials will include use of the BioSticker medical device for the continuous collection of vital sign and physiological data …

BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials Read More »

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and provider organizations that include this approach to testing. At a …

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease Read More »

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported promising phase 2 trial results from bemarituzumab in November. The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric …

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug Read More »

Agilent to Acquire Resolution Bioscience for $695M

Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally The acquisition will bring together Resolution’s noninvasive liquid biopsy platform that …

Agilent to Acquire Resolution Bioscience for $695M Read More »

Dr. Gundry’s The Plant Paradox Is Wrong

A book purported to expose “hidden dangers” in healthy foods doesn’t even pass the whiff test. I started getting emails about The Plant Paradox, a book purporting to expose “the hidden dangers in ‘healthy’ foods that cause disease and weight gain”—foods like beans, whole grains, and tomatoes. Hidden dangers? The author’s talking about lectins in …

Dr. Gundry’s The Plant Paradox Is Wrong Read More »

How digital health impacts the development and adoption of cancer immunotherapies [Sponsored]

In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.

Merck & Co axes Keytruda lung cancer niche amid FDA crackdown

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing data. Keytruda had been granted accelerated approval in metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least …

Merck & Co axes Keytruda lung cancer niche amid FDA crackdown Read More »

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics showing the risk of death and hospitalization from covid-19 rises …

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair? Read More »

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall …

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali Read More »

FDA to quickly review Incyte’s Jakafi in chronic GVHD

The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids. The US pharma, which has partnered with Novartis to develop this first-in-class JAK1/JAK2 inhibitor, said the FDA will review data from the phase 3 REACH 3 study comparing Jakafi to …

FDA to quickly review Incyte’s Jakafi in chronic GVHD Read More »

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non-small cell lung cancer patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which has become the go-to …

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer Read More »

Limited access to cancer biomarker testing in Europe, report finds

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report. The report from European Federation of Pharmaceutical Industries and Associations (EFPIA) shows the results of research conducted in 2020 to assess the availability, quality and reimbursement of biomarker tests …

Limited access to cancer biomarker testing in Europe, report finds Read More »

Zynteglo halt re-ignites viral vector safety concerns; analysts

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface.  That’s the view of analysts at Jefferies, who suggest it could “re-ignite concerns over the …

Zynteglo halt re-ignites viral vector safety concerns; analysts Read More »

AZ withdraws Imfinzi in US bladder cancer use after trial failure

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US. AZ’s share price ticked downwards after the announcement that it will stop marketing Imfinzi, a PD-L1 class immunotherapy, for previously treated adult patients with advanced or metastatic bladder cancer. It’s news that will …

AZ withdraws Imfinzi in US bladder cancer use after trial failure Read More »

Astellas/Seagen prepare full US filing of bladder cancer drug Padcev

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend. To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data …

Astellas/Seagen prepare full US filing of bladder cancer drug Padcev Read More »

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain …

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer Read More »

Does Nutritional Yeast Trigger Crohn’s Disease?

Is the exaggerated reaction of many Crohn’s disease patients to baker’s, brewer’s, and nutritional yeast just a consequence of their inflamed leaky gut, or might the yeast be a contributing cause? “Baker’s Yeast in Crohn’s Disease—Can It Kill You?” is the inflammatory title (no pun intended) of a 1999 journal article. Crohn’s disease is an …

Does Nutritional Yeast Trigger Crohn’s Disease? Read More »

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer

Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer. The companies are asking for an accelerated approval based on phase 2 data, which will have to be confirmed by data from a larger trial that will provide survival data. The …

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer Read More »

Health Plans Must Go Beyond the ONC Mandate and Prioritize Member Experience

Minal Patel, CEO of Abacus Insights Laurent Rotival, SVP, Strategic Technology Solutions & CIO, Cambia Solutions We are all frustrated when there’s a glitch with our online banking, or if bandwidth problems interfere with streaming the movie we want to watch. Imagine how individuals will react when the results of a cancer screening don’t find …

Health Plans Must Go Beyond the ONC Mandate and Prioritize Member Experience Read More »

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

MEDSIR, a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II clinical trial to demonstrate that in patients with HER2-positive early breast cancer with a good prognosis, a chemotherapy-free therapeutic approach can be as effective as the current standard of care, which involves the use of this generally more toxic …

A study to avoid chemotherapy in patients with early HER-2+ breast cancer Read More »

Why Cancer Registries are Part of America’s Fight for Racial Equality

Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white …

Why Cancer Registries are Part of America’s Fight for Racial Equality Read More »

Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears

When her gynecologist recommended genetic testing, Mai Tran was reluctant. “I didn’t really want to do it,” recalled Tran, who had just turned 21 and was living in New York City, “but she kept on emailing me about it and was really adamant that I do it.” Tran knew she had an elevated risk of …

Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears Read More »

Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others

Walgreens appoints Rosalind (Roz) Brewer as the company’s Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman of the Board of WBA. Brewer, 58, will become the …

Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others Read More »

Treating Advanced Prostate Cancer with Diet

Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer for early stage, localized, watch-and-wait cancer. What about for more advanced stage life-threatening disease? Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer by making men’s …

Treating Advanced Prostate Cancer with Diet Read More »

Action needed to preserve the six protected classes

In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing five-year Part D Payment Modernization Model. This model would provide “formulary flexibility” by exempting Part D plans in the Model from some of Part …

Action needed to preserve the six protected classes Read More »

A Patient Engagement Strategy Needs to Deliver a Holistic Experience

Chris Evanguelidi, Director, Enterprise Healthcare Market for Redpoint Global Inc. Researchers from Johns Hopkins published a study in October on the impact of the pandemic on health care delivery. Among its findings, the data show a 21.4% decrease in primary care visits in Q2 of 2020, compared against the average volume of Q2 visits for …

A Patient Engagement Strategy Needs to Deliver a Holistic Experience Read More »

Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network

What You Should Know: – Syapse raises 68M in equity investment  led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence  through Syapse’s Learning Health Network. – The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world data to …

Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network Read More »

Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M

What You Should Know: –  Volpara Health, an integrated breast care platform assisting in the delivery of personalized patient care has acquired breast cancer risk assessment platform CRA Health. – CRA Health, LLC, is a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital. Today the company delivers more …

Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M Read More »

AZ/Daiichi Sankyo’s partnership makes progress in lung cancer

AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership. Results announced at the World Conference on Lung Cancer came from Enhertu (trastuzumab deruxtecan), which targets cancers expressing the HER2 receptor and is already approved in certain lung and bladder cancers expressing …

AZ/Daiichi Sankyo’s partnership makes progress in lung cancer Read More »

Coconut Oil and the Boost in HDL “Good” Cholesterol

The effects of coconut oil were compared to butter and tallow. Even if virgin coconut oil and other saturated fats raise LDL “bad” cholesterol, isn’t that countered by the increase in HDL “good” cholesterol? According to “the experience and wisdom of 200 of the country’s leading experts in cardiovascular diseases,” in a report representing 29 …

Coconut Oil and the Boost in HDL “Good” Cholesterol Read More »

If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?

As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dementia patients near the end of their lives and people with autoimmune conditions. Recently, a number of readers have asked me whether older relatives with …

If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? Read More »

Pandemic ‘pushed lung cancer services back 20 years’, doctors warn

Governments must act to restore the damage done to lung cancer services during the pandemic in order to reduce further avoidable deaths, according to a report drawn up as part of this week’s World Economic Forum in Davos. The report, Learning Lessons from Across Europe – Prioritising Lung Cancer after COVID-19, highlights how lung cancer …

Pandemic ‘pushed lung cancer services back 20 years’, doctors warn Read More »

Careology joins forces with remote care support firm RedArc

Digital cancer care platform Careology has joined forces with RedArc, which provides long-term support for people with serious illnesses. RedArc has a team of registered nurses that provide support and expert advice by phone to people after referral from insurers, trade unions and groups such as trade unions. The new partnership provides RedArc nurses with …

Careology joins forces with remote care support firm RedArc Read More »

To Beat COVID-19, We Need A Modern Approach to Public Health Data

Ed Simcox, Chief Strategy Officer at LifeOmic The COVID-19 pandemic, which has taken 270,000 American lives to date, has shined a light on another crisis — the U.S. currently has no standardized system for reporting public health data. Health departments all over the country resort to using paper, fax, phone, and email to transmit and …

To Beat COVID-19, We Need A Modern Approach to Public Health Data Read More »

ICYMI: Cancer death rate continues decline due to advances in treatment

For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has …

ICYMI: Cancer death rate continues decline due to advances in treatment Read More »

Do the Pros of Brown Rice Outweigh the Cons of Arsenic?

Are there unique benefits to brown rice that would justify keeping it in our diet despite the arsenic content? For years, warnings had been given about the arsenic levels in U.S. rice potentially increasing cancer risk, but it had never been put to the test until a study out of Harvard. The finding? “Long-term consumption …

Do the Pros of Brown Rice Outweigh the Cons of Arsenic? Read More »

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab). This latest indication adds to Enhertu first approval at the end of 2019 for advanced HER2-positive breast cancer after two or more HER2-targeted regimens. Around one in five gastric …

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication Read More »

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US authorities. In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to …

Ex-Merck & Co scientist accused of stealing trade secrets could face jail Read More »

FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program

What You Should Know: – FCC announces initial 14 pilot project selected for $100M Connected Care Pilot Program that will support connected care service across the country and focus on low-income and veteran patients. The Federal Communications Commission (FCC) today announced an initial set of 14 pilot projects with over 150 treatment sites in 11 …

FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program Read More »

NICE recommends interim funding for GSK’s Zejula in ovarian cancer

Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. Zejula competes with AstraZeneca/Merck & Co’s PARP inhibitor class rival Lynparza (olaparib) but in this case it has an advantage in this maintenance therapy use as it can be used …

NICE recommends interim funding for GSK’s Zejula in ovarian cancer Read More »

Is White Rice a Yellow-Light or Red-Light Food?

Arsenic is not just considered to be a carcinogen; it’s also designated as a “nonthreshold carcinogen, meaning that any dose, no matter how small, carries some cancer risk”—so there really isn’t a “safe” level of exposure. Given that, it may be reasonable to “use the conservative ALARA” approach, reducing exposure As Low As Reasonably Achievable. …

Is White Rice a Yellow-Light or Red-Light Food? Read More »

Boehringer to investigate ‘dark antigens’ with UK cancer specialist Enara

Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07bn). Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that …

Boehringer to investigate ‘dark antigens’ with UK cancer specialist Enara Read More »

How Much Arsenic in Rice Is Too Much?

What are some strategies to reduce arsenic exposure from rice? Those who are exposed to the most arsenic in rice are those who are exposed to the most rice, like people who are eating plant-based, gluten-free, or dairy-free. So, at-risk populations are not just infants and pregnant women, but also those who may tend to …

How Much Arsenic in Rice Is Too Much? Read More »

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor …

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Read More »

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

Shots: The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical immunomics database of 58B+ immune cell receptors and antigens AstraZeneca …

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer Read More »

COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021

What You Should Know: – COVID-19 care deferrals lead to three major boomerang conditions that payers and providers must proactively address in 2021, according to a newly released report by Prealize. – COVID-19’s hidden victims—those who avoided or deferred care during the pandemic—will increasingly return to the healthcare system, and many will be diagnosed with …

COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021 Read More »

How Risky Is the Arsenic in Rice?

Getting rice down to the so-called safe water limit for arsenic would still allow for roughly 500 times greater cancer risk than is normally considered acceptable. Given the level of arsenic in rice, how could we figure out how much rice is too much? There are no U.S. standards for arsenic in rice, even though …

How Risky Is the Arsenic in Rice? Read More »

Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech

ImaginAb has signed a deal with Pfizer, which it hopes will help it to gather information necessary for approval of its tumour imaging agent as a medical device in markets in the US and other countries. The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can …

Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech Read More »

Why cell therapy manufacture is a team sport

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build …

Why cell therapy manufacture is a team sport Read More »

Meaningful Use of Genomics Requires Informatics Beyond EMRs

Assaf Halevy, Founder and CEO of 2bPrecise Electronic medical records (EMRs) are widely expected to serve as a cornerstone technology that drives the delivery of modern patient care.  But can the EMR alone support all the informatics capabilities required by an ever-evolving healthcare industry? The rapid growth of precision medicine, particularly the use of genetic …

Meaningful Use of Genomics Requires Informatics Beyond EMRs Read More »

DaVita & RenalytixAI Partner for Early Risk Identification to Help Slow Kidney Disease Progression

What You Should Know: – RenalytixAI and DaVita announce a program partnership that aims to slow kidney disease progression and improve outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). – This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management to …

DaVita & RenalytixAI Partner for Early Risk Identification to Help Slow Kidney Disease Progression Read More »

2020’s Top 20 Digital Health M&A Deals Totaled $50B

Teladoc Health and Livongo Merge The combination of Teladoc Health and Livongo creates a global leader in consumer-centered virtual care. The combined company is positioned to execute quantified opportunities to drive revenue synergies of $100 million by the end of the second year following the close, reaching $500 million on a run-rate basis by 2025. …

2020’s Top 20 Digital Health M&A Deals Totaled $50B Read More »

Arsenic in Rice Milk, Rice Krispies, and Brown Rice Syrup

I recommend people switch away from using rice milk For kids and teens, the amount of arsenic flowing through their bodies was found to be about 15 percent higher for each quarter cup of rice consumed per day, and a similar link was found in adults. A study of pregnant women found that consuming about …

Arsenic in Rice Milk, Rice Krispies, and Brown Rice Syrup Read More »

Patient-First Model: High Tech Meets High Touch for Individuals with Rare Disorders

Donovan Quill, President and CEO, Optime Care Industry experts state that orphan drugs will be a major trend to watch in the years ahead, accounting for almost 40% of the Food and Drug Administration approvals this year. This market has become more competitive in the past few years, increasing the potential for reduced costs and broader patient accessibility. …

Patient-First Model: High Tech Meets High Touch for Individuals with Rare Disorders Read More »

Arsenic in Infant Rice Cereal

When it comes to rice and rice-based products, pediatric nutrition authorities have recommended that arsenic intake should be as low as possible. “The US Food and Drug Administration (FDA) has been monitoring the arsenic content in foods” for decades, yet despite the “well-established science describing the health risks associated with arsenic exposure, no standards have …

Arsenic in Infant Rice Cereal Read More »

BMS calls time on brain cancer trial as Opdivo misses second target

Bristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of brain cancer, saying that it looks unlikely to produce a survival benefit in the disease. BMS said an independent committee had reviewed data from the phase 3 CheckMate-548 trial in newly diagnosed MGMT-methylated glioblastoma multiforme and concluded …

BMS calls time on brain cancer trial as Opdivo misses second target Read More »

How to Cook Rice to Lower Arsenic Levels

Boiling rice like pasta reduces arsenic levels, but how much nutrition is lost? Cooking rice in a high water-to-rice ratio reduces toxic arsenic content, which I discuss in my video How to Cook Rice to Lower Arsenic Levels. What exactly does that mean? Well, as you can see at 0:16 in my video, if you …

How to Cook Rice to Lower Arsenic Levels Read More »

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Servier Acquires Agios’ Cancer Portfolio in a USD 2 Billion Deal The year is a prime witness of pricey deals and acquisitions in the pharmaceutical industry. To leave its mark, another player decided to hop onto the list. French drugmaker Servier has announced the acquisition of the Oncology business of Agios Pharmaceutical in a deal …

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Read More »

AZ’s Tagrisso gets new early lung cancer use in US

AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its use to a group of patients with early-stage disease. The new use covers adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after a potentially curative operation. Patients must …

AZ’s Tagrisso gets new early lung cancer use in US Read More »

MacroGenics’ HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data gathered so far in advanced disease. Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of …

MacroGenics’ HER2 breast cancer drug Margenza approved in US Read More »

Amgen files KRAS trailblazer sotorasib with FDA for lung cancer

Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the disease. The drug was the first targeted at the mutation known as KRAS to show activity in the clinic and provided the biggest talking point at the American Society of …

Amgen files KRAS trailblazer sotorasib with FDA for lung cancer Read More »

COVID-19 and Reductions in Cancer Mortality

That is the topic of a commentary I wrote with co-authors Joanna MacEwan and Farzad Ali, titled “Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?” An excerpt is below: Cancer mortality rates have fallen significantly over the last 20 years. Between 2000 and 2010, overall age-adjusted …

COVID-19 and Reductions in Cancer Mortality Read More »

Readers and Tweeters Defend Front-Line Nurses and Blind Us With Science

Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. The demand for skilled nurses during the pandemic is through the roof! Travel nurses command a hefty salary and they are worth every penny… #COVID19 #pandemic #RN https://t.co/gYQpkHqaoX — Talmage …

Readers and Tweeters Defend Front-Line Nurses and Blind Us With Science Read More »

Which Rice Has the Least Amount of Arsenic: Black, Brown, Red, White, or Wild?

Brown rice contains more arsenic than white rice, but the arsenic in brown rice is less absorbable, so how does it wash out when you compare the urine arsenic levels of white-rice eaters to brown-rice eaters? Arsenic in rice is a cause for concern, according to a consensus statement by the European and North American …

Which Rice Has the Least Amount of Arsenic: Black, Brown, Red, White, or Wild? Read More »

Report: More than 1,300 medicines and vaccines in development to help fight cancer

Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific cancer types. Since peaking in 1991, the death rate associated with cancer declined by 29%, which translates to 2.9 million fewer cancer deaths. The most …

Report: More than 1,300 medicines and vaccines in development to help fight cancer Read More »

Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer

Shots: Roche launches the cobas PIK3CA mutation test for patients with advanced/ m-BC in countries accepting the CE mark The IVT test is a real-time PCR test for the qualitative detection & identification of 17 mutations in exons 2, 5, 8, 10 & 21 in the gene encoding the catalytic subunit of PIK3CA in DNA …

Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer Read More »

5 big healthcare lawsuits of 2020

Some of the biggest legal stories of the year include patients attempting to mount a class action lawsuit against Mayo Clinic after an employee improperly viewed more than 1,600 health records and the Supreme Court hearing opening arguments in a case challenging the constitutionality of the ACA’s individual mandate.

Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer

Shots: The recommendation is based on a P-II DESTINY-Breast01 study assessing trastuzumab deruxtecan in patients with HER2 positive unresectable/ m-BC prior treated with trastuzumab emtansine The trial demonstrated a meaningful & durable activity in patients who had received two or more prior anti-HER2 therapies. The safety & tolerability profile of the therapy was consistent with …

Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer Read More »

LeenTaaS Secures $130M for ML Platform to Help Hospitals Achieve Operational Excellence

What You Should Know: – LeanTaaS raises $130 million in Series D Funding to strengthen its machine learning platform to continue helping hospitals achieve operational excellence during a time where they are facing mounting financial pressures due to COVID-19.  – LeanTaaS provides software solutions that combine lean principles, predictive analytics, and machine learning to transform …

LeenTaaS Secures $130M for ML Platform to Help Hospitals Achieve Operational Excellence Read More »

Pair Team Emerges Out of Stealth with $2.7M to Automate Primary Care Operations

What You Should Know: – San Francisco-based digital health startup Pair Team emerges out of stealth with $2.7M in seed funding backed by Kleiner Perkins, Craft Ventures, & YC. – Pair Team provides both a remote team and AI that automates workflows, provides infrastructure & improves medical practices — efficiencies and billing as you’d expect, …

Pair Team Emerges Out of Stealth with $2.7M to Automate Primary Care Operations Read More »

What HCPs think about COVID-19’s impact on cancer

COVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as a key worry. CREATION.co’s Lara Meyer explores why HCPs need more support. The COVID-19 pandemic has been mainstream headline news throughout 2020 and continues to have a profound impact on all our lives. A key concern that …

What HCPs think about COVID-19’s impact on cancer Read More »

Cancer Risk from Arsenic in Rice and Seaweed

A daily half-cup of cooked rice may carry a hundred times the acceptable cancer risk of arsenic. What about seaweed from the coast of Maine? “At one point during the reign of King Cotton, farmers in the south central United States controlled boll weevils with arsenic-based pesticides, and residual arsenic still contaminates the soil.” Different …

Cancer Risk from Arsenic in Rice and Seaweed Read More »

FDA puts Bellicum’s cancer cell therapy trial on hold

The FDA has placed a clinical hold on a phase 1/2 trial of Bellicum’s cancer cell therapy BPX-601, following a patient death. Houston, Texas-based Bellicum said that the regulator had placed recruitment and dosing on hold in the dose-escalation trial in patients with previously treated metastatic pancreatic cancer or prostate cancer. Bellicum is hoping to …

FDA puts Bellicum’s cancer cell therapy trial on hold Read More »

Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year. The California biotech had reached an agreement with Iconic and Zymeworks giving the option on the drug in May last year. Probably best known for the cancer drug Cabometyx …

Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC Read More »

The Effects of Too Much Arsenic in the Diet

Even at low-level exposure, arsenic is not just a class I carcinogen, but may also impair our immune function and increase our risk of cardiovascular disease and diabetes. When people hear about arsenic, they think of it as an acute poison, and, indeed, a tiny amount—a hundred milligrams, about one-tenth the weight of a paperclip—could …

The Effects of Too Much Arsenic in the Diet Read More »

Merck KGaA signs DNA damage response cancer deal with Artios Pharma

Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP) inhibitor drugs. These target the inherent genetic instability in certain …

Merck KGaA signs DNA damage response cancer deal with Artios Pharma Read More »

Virtual Engagement During COVID Pushes Paradigm Shift for Physician Training and Patient Care

Shalini Shah, MD is Vice-Chair and Associate Professor, Department of Anesthesiology & Perioperative Care, and Enterprise Director of Pain Services, UC Irvine Health The dominant presence of COVID-19 has not meant the absence of cancer, ear infections, heart attacks, chronic pain, or other illnesses that need attention and care. Physicians have continued treatment for all …

Virtual Engagement During COVID Pushes Paradigm Shift for Physician Training and Patient Care Read More »

Genmab axes development of AXL-targeting cancer drug enapotamab vedotin

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial. The drug is an antibody-drug conjugate where a monoclonal antibody is linked to monomethyl auristatin, a cancer-killing “payload”. It is targeted against AXL, a signalling molecule that is overexpressed in several haematologic and …

Genmab axes development of AXL-targeting cancer drug enapotamab vedotin Read More »

Why Was Chicken the Primary Source of Arsenic Exposure in Children?

What was the National Chicken Council’s response to public health authorities calling for the industry to stop feeding arsenic-based drugs to poultry? “Dietary practices influence our exposure to pesticides, toxic heavy metals, persistent organic pollutants, and industrial pollutants….A diet high in fish and other animal products, for example, results in greater exposure to persistent organic compounds …

Why Was Chicken the Primary Source of Arsenic Exposure in Children? Read More »

Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin

Shots: The company has submitted an MAAA for BAT1706 to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the EU Member States, Iceland, Norway, and Liechtenstein The submission of the MAA for BAT1706 marks it as the first ex-China MAA/ BLA submission. The BLA of the biosimilar for metastatic carcinoma …

Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin Read More »

Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others

Neela Montgomery, EVP & President at CVS Pharmacy/Retail CVS Health Corporation names Neela Montgomery Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020. Montgomery will oversee the company’s 10,000 pharmacies across the United States. Montgomery, currently a Board Partner at venture capital firm Greycroft, most recently served as chief executive officer of …

Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others Read More »

Novartis set to overcome $14 billion patent cliff say analysts

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster …

Novartis set to overcome $14 billion patent cliff say analysts Read More »

New Legal Push Aims to Speed Magic Mushrooms to Dying Patients

Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread. Just 48 and the mother of two teenagers, Baldeschwiler was diagnosed with stage 4 metastatic breast cancer after discovering a small lump on her chest, no bigger than a …

New Legal Push Aims to Speed Magic Mushrooms to Dying Patients Read More »

COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data

What You Should Know: – COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care, has secured $34M in funding. – Access to over one million patient data records and additional funding support enhanced real-world data and analytics services in oncology. COTA, Inc., a Boston, MA-based healthcare technology company …

COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data Read More »

Volaris Group Acquires Clinical Workforce & Workflow Platform medaptus

What You Should Know: – Volaris Group acquires medaptus, a clinical workforce, and workflow solutions that empower healthcare delivery entities to achieve their desired patient, clinical and financial outcomes. Today, Volaris Group has acquired medaptus, a healthcare technology company that removes the administrative burden from hospital and group practice operations to enable higher efficiency throughput. …

Volaris Group Acquires Clinical Workforce & Workflow Platform medaptus Read More »

Lead Pharma signs $308m deal to develop small molecule drugs with Roche

Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases. The deal will revolve around a single undisclosed drug target and will see the Dutch biotech receive 10 million euros up front from Roche. Lead will lead the selection of a pre-clinical drug …

Lead Pharma signs $308m deal to develop small molecule drugs with Roche Read More »

The Antioxidant Power of Açaí vs. Apples

There are so many açaí products on the market now, from frozen pulp in smoothie packs to freeze-dried powder and supplements. How is it eaten traditionally? “In the Brazilian Amazon, the Indian tribes of the forest cut down the tree and eat the palm heart…then urinate on the rest of the tree to attract a …

The Antioxidant Power of Açaí vs. Apples Read More »

Fresh doubts over BMS’ merger payout as FDA delays key drug review

Holders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out after the company said COVID-19 travel restrictions are delaying a key regulatory review. Shareholders in Celgene received a contingent value right (CVR) at the time of the company’s $74 billion merger with BMS last year, which pay …

Fresh doubts over BMS’ merger payout as FDA delays key drug review Read More »

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures. Founded in 2016 as a spin-out …

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy Read More »

Merck & Co/Eisai eye kidney cancer use for immunotherapy combination

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated patients. Keytruda (pembrolizumab) and Lenvima (lenvatinib) outperformed standard care – Pfizer’s Sutent (sunitinib) – in untreated patients with advanced renal cell carcinoma when measured …

Merck & Co/Eisai eye kidney cancer use for immunotherapy combination Read More »

M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices

What You Should Know: – RxVantage has acquired onPoint Oncology to provide cancer care teams with on-demand access to educational resources, reimbursement data, and analytics. – The acquisition of onPoint Oncology builds on RxVantage’s rapidly expanding digital offerings for providers. In April, RxVantage launched Virtual Meetings to help providers reestablish access to life science experts amidst the disruptions caused …

M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices Read More »

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously treated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVie’s Venclyxto and Roche’s Gazyva. The decision by NICE allows for the 12-month fixed duration treatment option based on data from the phase 3 CLL14 trial. This showed the combination …

NICE backs chemo-free CLL combination from AbbVie and Roche Read More »

Can Soy Prevent and Treat Prostate Cancer?

As I discuss in my video The Role of Soy Foods in Prostate Cancer Prevention and Treatment, a compilation of 13 observational studies on soy food consumption and the risk of prostate cancer found that soy foods appear to be “protective.” What are observational studies? As opposed to interventional studies, in observational studies, researchers observe …

Can Soy Prevent and Treat Prostate Cancer? Read More »

New cancer drugs saved 1.3 million lives

That is the finding from a recent paper by myself and co-authors Joanna MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, and Katharine Batt. An excerpt from the paper is below: Between 2000 and 2016, deaths per 100,000 population across the 15 most common tumor types declined by 24%. Additionally, 10.2 new indications were approved per …

New cancer drugs saved 1.3 million lives Read More »

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left to right): Alex Zhavoronkov, Founder & CEO, Insilico Medicine; Li …

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China Read More »

After two decades, NICE begins consultation on drug assessment methods

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics. NICE has been assessing medicines for 21 years using the Quality Adjusted Life Year (QALY) – the cost to ‘buy’ a patient a year of quality life – as its …

After two decades, NICE begins consultation on drug assessment methods Read More »

Merck & Co buys cancer biotech VelosBio for $2.75bn

Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash. Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to …

Merck & Co buys cancer biotech VelosBio for $2.75bn Read More »

AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Shots: The approval is based on a biomarker subgroup analysis of P-III PAOLA-1 study assessing Lynparza + bevacizumab vs bevacizumab alone as 1L maintenance treatment in patients with newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometrioid ovarian, fallopian tube, peritoneal cancer who had CR/PR to 1L treatment with Pt. based CT and bevacizumab Results: reduction …

AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer Read More »

Fermented or Unfermented Soy?

As you can see at the start of my video Fermented or Unfermented Soy Foods for Prostate Cancer Prevention?, there is an enormous variation in the rates of prostate cancer around the globe, with among the highest rates in the United States and lowest rates in Asia—though that may be changing. The largest increase in …

Fermented or Unfermented Soy? Read More »

Be in the room: Turning patient engagement to patient centricity

After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use. The avid blogger and passionate advocate retired from his R&D role four years ago to focus on his own health, and now works full time on making sure the …

Be in the room: Turning patient engagement to patient centricity Read More »

AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track

AstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely watched coronavirus vaccine trial. AZ said in its third quarter results statement that it is on track to meet its guidance for the year, with total revenue expected to grow by 8%-12% and core earnings per share …

AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track Read More »

FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer

What You Should Know: – The FDA just extended its research collaboration agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting cancer. – With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the pandemic on cancer treatment, with the opportunity to expand into …

FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer Read More »

Europe approves Roche’s Tecentriq liver cancer combination

The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients with the most common form of liver cancer. Tecentriq (atezolizumab) can be used with Avastin (bevacizumab) for adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not received systemic therapy. Approval is based on findings of …

Europe approves Roche’s Tecentriq liver cancer combination Read More »

Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer

Shots: The pivotal P-III MONALEESA-7 study assessing Kisqali + endocrine therapy vs PBO + endocrine therapy, in pre- & perimenopausal women with HR+/HER2- advanced or metastatic-BC The study met its 2EPs of OS, demonstrating a significant improvement in OS, and is consistent for the NSAI population & across exploratory subgroups, m-OS was not reached while …

Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer Read More »

Jounce shares crash after it abandons immunotherapy combination trial

Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy will likely fail to produce results in non-small cell lung cancer. Jounce was combining its vopratelimab with BMS’ already-approved Yervoy, hoping that the experimental drug will bolster the T-cell attack called in by the big pharma’s immunotherapy. …

Jounce shares crash after it abandons immunotherapy combination trial Read More »

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing globally The collaboration leverages Fusion’s TAT platform and expertise in …

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer Read More »

Sanofi to acquire Kiadis and NK cell tech for $353 million

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million). The French pharma is buying Kiadis for 5.45 euros per share in cash, an offer price representing a premium of 272% over the biotech’s closing price on Friday evening on …

Sanofi to acquire Kiadis and NK cell tech for $353 million Read More »

GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer

Shots: The approval is based on PRIMA study assessing Zejula (300mg qd), later amended to incorporate an individualised starting dose of Zejula (200 mg or 300 mg, qd) based on the patient’s baseline weight and/or platelet count Results: The PRIMA study improved PFS for patients treated with Zejula, regardless of biomarker status. In the HRd …

GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer Read More »

ANGLE raises £20m, eyes opportunity in immunotherapy trials

Liquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will be used to expand commercial opportunities. ANGLE’s Parsortix system detects and captures circulating tumour cells (CTCs) in blood for subsequent analysis. The company believes there is huge potential for its use in assessing patient response to immunotherapy …

ANGLE raises £20m, eyes opportunity in immunotherapy trials Read More »

What White Blood Cell Count Should We Shoot for?

At the start of my video What Does a Low White Blood Cell Count Mean?, you can see what it looks like when you take a drop of blood, smear it between two pieces of glass, and view at it under a microscope: a whole bunch of little, round, red blood cells and a few …

What White Blood Cell Count Should We Shoot for? Read More »

Exact Sciences buys cancer detection company Thrive for $2.15 billion

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a leader in the cancer-screening market. The Madison-based company has made …

Exact Sciences buys cancer detection company Thrive for $2.15 billion Read More »

Toxic positivity and grief: The reality of living through cancer

Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. No one gets through cancer unscathed. People are usually left with a mixture of treatment aftereffects, toxic positivity, and lingering anger to deal with. Megan-Claire Chase, a fierce patient advocate who has been blogging …

Toxic positivity and grief: The reality of living through cancer Read More »

FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment

What You Should Know: – FDA awards AppliedVR Breakthrough Device designation for treating treatment-resistant fibromyalgia and chronic intractable lower back pain – AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive-behavioral therapy (CBT) principles and other behavioral methods. AppliedVR, a pioneer advancing the next generation of digital medicine, today announced its EaseVRx …

FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment Read More »

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the world’s largest human pathology specimen repository in order to enhance …

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository Read More »

Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes

What You Should Know: – Today, Blue Cross and Blue Shield of North Carolina partners with Carrot Inc. and Virta Health to help address two of the largest ongoing health issues facing Americans today – smoking and type 2 diabetes. – Virta and Carrot’s programs will be available to individual under-65 members and fully insured …

Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes Read More »

What About the Trans Fat in Animal Fat?

The years of healthy life lost due to our consumption of trans fats are comparable to the impact of conditions like meningitis, cervical cancer, and multiple sclerosis. But, if “food zealots” get their wish in banning added trans fats, what’s next? I explore this in my video Banning Trans Fat in Processed Foods but Not …

What About the Trans Fat in Animal Fat? Read More »